1. Home
  2. ANDE vs SNDX Comparison

ANDE vs SNDX Comparison

Compare ANDE & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANDE
  • SNDX
  • Stock Information
  • Founded
  • ANDE 1947
  • SNDX 2005
  • Country
  • ANDE United States
  • SNDX United States
  • Employees
  • ANDE N/A
  • SNDX N/A
  • Industry
  • ANDE Farming/Seeds/Milling
  • SNDX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ANDE Industrials
  • SNDX Health Care
  • Exchange
  • ANDE Nasdaq
  • SNDX Nasdaq
  • Market Cap
  • ANDE 1.4B
  • SNDX 1.3B
  • IPO Year
  • ANDE N/A
  • SNDX 2016
  • Fundamental
  • Price
  • ANDE $41.96
  • SNDX $15.36
  • Analyst Decision
  • ANDE Buy
  • SNDX Strong Buy
  • Analyst Count
  • ANDE 3
  • SNDX 10
  • Target Price
  • ANDE $51.67
  • SNDX $38.40
  • AVG Volume (30 Days)
  • ANDE 505.1K
  • SNDX 2.0M
  • Earning Date
  • ANDE 11-03-2025
  • SNDX 11-04-2025
  • Dividend Yield
  • ANDE 1.90%
  • SNDX N/A
  • EPS Growth
  • ANDE N/A
  • SNDX N/A
  • EPS
  • ANDE 2.35
  • SNDX N/A
  • Revenue
  • ANDE $11,539,093,000.00
  • SNDX $77,933,000.00
  • Revenue This Year
  • ANDE $9.10
  • SNDX $641.22
  • Revenue Next Year
  • ANDE $2.78
  • SNDX $110.64
  • P/E Ratio
  • ANDE $17.45
  • SNDX N/A
  • Revenue Growth
  • ANDE N/A
  • SNDX 2126.66
  • 52 Week Low
  • ANDE $31.03
  • SNDX $8.58
  • 52 Week High
  • ANDE $51.58
  • SNDX $22.50
  • Technical
  • Relative Strength Index (RSI)
  • ANDE 60.09
  • SNDX 47.93
  • Support Level
  • ANDE $40.81
  • SNDX $14.93
  • Resistance Level
  • ANDE $42.42
  • SNDX $15.99
  • Average True Range (ATR)
  • ANDE 0.98
  • SNDX 0.77
  • MACD
  • ANDE 0.13
  • SNDX -0.03
  • Stochastic Oscillator
  • ANDE 87.79
  • SNDX 26.15

About ANDE Andersons Inc. (The)

Andersons Inc is a diversified company with its main focus in the agriculture sector. Its operations are segmented into Trade, Renewables, and Nutrient & Industrial. The Trade segment, which generates the majority of the revenue, is engaged in the movement of physical commodities such as whole grains, grain products, feed ingredients, and domestic fuel products, among other agricultural commodities. Geographically, the company generates the majority of its revenue from the United States and the rest from Canada, Mexico, Egypt, Switzerland, and other markets.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: